Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy

Research output: Contribution to journalArticle

Standard

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy. / Tayebjee, Muzahir; Lim, Hoong; Macfadyen, Robert; Lip, Gregory.

In: Diabetes Care, Vol. 27, No. 8, 01.08.2004, p. 2049-51.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{10e37d9ec7b341c495a27a97199b8ce5,
title = "Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy",
author = "Muzahir Tayebjee and Hoong Lim and Robert Macfadyen and Gregory Lip",
year = "2004",
month = aug,
day = "1",
doi = "10.2337/diacare.27.8.2049",
language = "English",
volume = "27",
pages = "2049--51",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association",
number = "8",

}

RIS

TY - JOUR

T1 - Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy

AU - Tayebjee, Muzahir

AU - Lim, Hoong

AU - Macfadyen, Robert

AU - Lip, Gregory

PY - 2004/8/1

Y1 - 2004/8/1

U2 - 10.2337/diacare.27.8.2049

DO - 10.2337/diacare.27.8.2049

M3 - Article

C2 - 15277439

VL - 27

SP - 2049

EP - 2051

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 8

ER -